The global aorto-iliac occlusive disease (iliac disease) treatment market size was estimated at USD 2.15 billion in 2024 and is projected to reach USD 2.95 billion by 2030, growing at a CAGR of 5.5% from 2025 to 2030. Aorto-Iliac Occlusive Disease is a medical condition characterized by the narrowing or blockage of the large arteries in the abdomen and pelvis, specifically the aorta and iliac arteries, which results in reduced blood flow to the lower extremities, leading to pain, mobility issues, and potential complications if left untreated.

A major factor driving growth in this market is the increasing prevalence of Peripheral Artery Disease (PAD), a condition that significantly contributes to the development of AIOD. According to the American Heart Association, PAD affects an estimated 200 million people worldwide. The rising incidence of PAD is largely attributed to factors such as aging populations, diabetes, and smoking, which collectively increase the risk of arterial blockages.

The growing number of PAD and AIOD cases has consequently heightened the demand for effective treatment options. This trend is driving the adoption of minimally invasive procedures, including iliac artery stenting and endovascular therapies, which are designed to restore proper blood flow, relieve symptoms such as leg pain, and improve mobility. The focus on less invasive interventions reflects both patient preference and advances in medical technology, supporting sustained growth in the AIOD treatment market.

Key Market Trends & Insights:

• North America dominated the global aorto-iliac occlusive disease (AIOD) treatment market, capturing the largest revenue share of 43.5% in 2024, reflecting the region’s advanced healthcare infrastructure, high adoption of minimally invasive procedures, and well-established cardiovascular care facilities.

• Within the region, the U.S. accounted for the largest market revenue share in North America in 2024, driven by increasing prevalence of peripheral artery disease, high patient awareness, and widespread access to innovative endovascular treatments.

• By end use, the hospitals segment led the market with a revenue share of 49.2% in 2024, as hospitals provide comprehensive care, including diagnostics, interventional procedures, and post-operative management, making them the preferred setting for AIOD treatment.

• By device type, the endovascular devices segment dominated with a revenue share of 87.5% in 2024, due to the growing preference for minimally invasive solutions, higher patient acceptance, and faster recovery times compared to traditional surgical interventions.

• By procedure, the endovascular procedures segment led the market with a revenue share of 61.1% in 2024, reflecting the increasing adoption of angioplasty and stenting techniques that restore proper blood flow while minimizing complications and hospitalization time.

Order a free sample PDF of the Aorto-Iliac Occlusive Disease Treatment Market Intelligence Study, published by Grand View Research.

Market Size & Forecast:

• 2024 Market Size: USD 2.15 Billion

• 2030 Projected Market Size: USD 2.95 Billion

• CAGR (2025-2030): 5.5%

• North America: Largest market in 2024

• Asia Pacific: Fastest growing market

Key Companies & Market Share Insights:

Some of the key players operating in the aorto-iliac occlusive disease (AIOD) treatment industry include Boston Scientific Corporation, BD, and Abbott, which hold significant positions due to their extensive product portfolios, technological expertise, and global market presence. These companies employ strategic approaches that focus on understanding the strengths and weaknesses of major competitors, anticipating future market trends, opportunities, and challenges, and making proactive decisions informed by insights into emerging technologies and evolving patient needs.

In addition to these established players, several emerging companies are gaining recognition within the AIOD treatment market. For example, Biotronik SE & Co KG and Getinge AB are notable entrants that are leveraging innovation, specialized product offerings, and targeted market strategies to establish a foothold in this competitive landscape. By focusing on advanced device technologies, minimally invasive procedures, and improved patient outcomes, these emerging companies are positioned to contribute to the overall growth and evolution of the AIOD treatment industry.

Key Players

• BD.

• Bentley InnoMed

• Scitech Medical

• Abbott

• Boston Scientific Corporation

• W. L. Gore & Associates, Inc.

• Medtronic

• Cook

• Terumo Corporation

• iVascular

• Getinge AB

• Biotronik SE & Co KG

Explore Horizon Databook – The world's most expansive market intelligence platform developed by Grand View Research.

Conclusion:

The global aorto-iliac occlusive disease (AIOD) treatment market is expected to grow steadily, driven by the increasing prevalence of peripheral artery disease (PAD) and the rising need for effective, minimally invasive therapies. Endovascular devices and procedures are becoming the preferred choice over traditional open surgeries due to faster recovery, reduced complications, and improved patient outcomes. Hospitals remain the primary care setting for AIOD treatment, providing specialized vascular care, advanced imaging, and post-procedure support. While North America currently leads the market, developing regions with a growing PAD burden are expected to experience accelerated adoption, highlighting expanding global demand for AIOD interventions.